References
- Alzheimer A. Ueber eine eigenartige Erkrankung der hirnrinde. Algemeine Zeitschrift fuer Psychiatrie und Psychisch-Gerichtliche Medizin 1907; 64: 146–148
- Kidd M. Alzheimer's disease. N Eng J Med 1964; 314: 964–972
- Glenner G G, Wong C W. Alzheimer's disease and Down's syndrome: sharing a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Comm 1984; 122: 1131–1135
- Masters C L, Simms G, Weinmann N A, Multhaup G, McDonald B L, Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc Natl Acad Sci 1985; 82: 4245–4249
- Selkoe D J, Abraham C R, Podlisny M B, Duffy L K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 1986; 46: 1820–1834
- Roher A, Wolfe A D, Palutke M, Kuruga D. Purification, ultrastrucure, and chemical analysis of Alzheimer's disease amyloid plaque core protein. Proc Natl Acad Sci 1986; 83: 2662–2666
- Goldgaber D, Lerman M J, McBride O W, Saffiotti V, Gadjusek D C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987; 235: 877–884
- Robakis N K, Ramakrishna N, Wolfe G, Wisniewski H M. Molecular cloning and characterization of cDNA encoding the cerebral vascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci 1987; 84: 4190–4194
- Kang J, Lemaire H G, Unterback A, Salbaum J M, Masters C L, Grezeschik K H, Multhaup G, Beyreuther K, Muller Hill B. The precursor of Alzheimer disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 331: 530–532
- Tanzi R E, Gusella J F, Watkins P C, Bruns G AP, George St., Hyslop P, Van Keuren M L, Patterson D, Pajan S, Kumit D M, Neve R L. Amyloid β-protein gene; cDNA, mRNA distribution and genetic linkage near the Alzheimer locus. Science 1987; 235: 880–883
- Selkoe D J. Cell biology of the Amyloid β-Protein precursor and the mechanism of Alzheimer's disease. Ann Rev Cell Biol 1994; 10: 373–403
- Selkoe D J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature Supp 1999; 399: A23–A31
- Vassar R, Bennett B D, Babu-Khan S, Kahn S, Mendiaz E A, Denis P, Teplow D B, Ross S, Amarante P, Loeloff R, Luo Y U, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski M A, Biere A L, Curran E, Burgess T, Louis J-C, Collins F, Treanor J, Rogers G, Citron M. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–741
- Eikelenboom P, Stam F C. Immunoglobulins and complement factors in senile plaques. Acta Neurol (Berl) 1982; 57: 239–242
- Abraham C R, Selkoe D J, Potter H. Immunohistochemical identification of the serine protease inhibitor alantichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988; 52: 487–501
- Snow A D, Wight T N. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 1989; 10: 481–497
- Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and Kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 1991; 541: 163–166
- Qiu W Q, Walsh D M, Ye Z, Vekrellis K, Zhang J, Podlisny M B, Rosner M R, Safavi A, Hersh L B, Selkoe D J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem 1998; 273: 32730–32738
- Yamin R, Malgeri E, McGraw W T, Sloane J A, Abraham C R. Metalloendopeptidase E.C.3.4.24.15 is necessary for Alzheimer's amyloid β peptide degradation. J Biol Chem 1999; 214: 17777–84
- Paresce D M, Chung H, Maxfield F R. Slow degradation of aggregates of the Alzheimer's disease amyloid betaprotein by microglial cells. J Biol Chem 1997; 272: 29390–29397
- Golabek A A, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem 1996; 271: 10602–10606
- Rebeck G W, Reiter J S, Strickland D K, Hyman B T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11: 575–580
- Yan S D, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stem D, Schmidt A M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685–691
- Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis?. Proc Natl Acad Sci 1997; 94: 2095–2097
- De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387–390
- Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398: 513–517
- Eikelenboom P, Zhan S S, van Gool W A, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Parmacol Sci 1994; 15: 447–450
- McGeer P L, McGeer E G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195–218